A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors
Latest Information Update: 02 Aug 2022
At a glance
- Drugs Cisplatin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 04 May 2022 New trial record
- 21 Apr 2022 According to a CSPC Pharmaceutical Group media release, company has obtained clinical trial approval granted by the National Medical Products Administration to conduct clinical trials of Cisplatin micelle in China.